Latest Bellicum Pharmaceuticals Inc. Stories

2014-03-17 08:29:24

NCI study to investigate whether third generation CAR T Cells can be eliminated if they become harmful HOUSTON, March 17, 2014 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. announced today that the first clinical study is underway of a Chimeric Antigen Receptor (CAR) T Cell therapy that incorporates a safety switch to enable rapid elimination of the administered T cells if they threaten the life or health of the patient. Researchers from the National Cancer Institute (NCI) have...

2014-01-07 08:30:56

Funds Will Expand Clinical Development of Company's Controlled Cellular Immunotherapies HOUSTON, Jan. 7, 2014 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. announced today that it has completed a second and final closing of its Series B financing, securing an additional $14.7 million and bringing the total raised in the round to $34.4 million. Current investors provided the additional funding, including AVG Ventures and Remeditex Ventures. The funding will be used to expand...

2011-03-25 07:00:00

HOUSTON, March 25, 2011 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced that the Company received notice of a $5.7 million company commercialization award from the Cancer Prevention and Research Institute of Texas ("CPRIT"). Bellicum was the only company recommended for funding in this second round of the commercialization award program. The award will fund personnel, manufacturing, and clinical testing of Bellicum's CaspaCIDe(TM) therapy, which promises to substantially...

2011-03-08 09:54:00

HOUSTON, March 8, 2011 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced the publication of studies comparing AP1903-activated iMyD88/CD40-transduced dendritic cells (DCs) to conventionally matured DCs, in the April 2011 issue of The Journal of Clinical Investigation (JCI). The studies, conducted by researchers at Baylor College of Medicine, explored the feasibility of a second generation DeCIDe(TM) vector that combines an inducible toll like receptor (TLR) adapter molecule,...

2011-02-18 07:09:00

ORLANDO, Fla., Feb. 18, 2011 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced the presentation of Phase I/II safety and efficacy data for BPX-101, a novel drug-activated dendritic cell vaccine for metastatic castrate resistant prostate cancer (mCRPC), in three separate posters at the 2011 Genitourinary Cancers Symposium held in Orlando, Florida on February 17 - 19, 2011. Three leading medical specialty societies co-sponsor the symposium, including the American Society of...

Word of the Day
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.